Zhang X-J, Kang Y-D, Xiao L, Li R-D, Ding G-S, Wang Z-X, Fu Z-R
Department of Organ Transplantation, Shanghai Changzheng Hospital, Second Military Medical University, Shanghai, China.
Transplant Proc. 2010 Nov;42(9):3779-83. doi: 10.1016/j.transproceed.2010.08.033.
Tacrolimus (Tac, FK506) is a widely used T-cell-targeted immunosuppression drug known as a calcineurin inhibitor. However, its pharmacologic effects on T-helper type 17 (Th17) cells have not been fully elucidated. Herein, we demonstrate that Tac inhibits Th17 cell differentiation and proliferation, and expression of IL-17 messenger RNA. The proposed mechanism is that Tac inhibits calcineurin and T-cell receptor stimulation-induced cell division. Because Th17 cells participate in allograft rejection, the results of the present study suggest a novel model of immunosuppression effects of Tac. In addition, they provide further implications for the therapeutic immunosuppression effects of Tac on allograft rejection.
他克莫司（Tac，FK506）是一种广泛使用的靶向T细胞的免疫抑制药物，属于钙调神经磷酸酶抑制剂。然而，其对17型辅助性T细胞（Th17细胞）的药理作用尚未完全阐明。在此，我们证明他克莫司可抑制Th17细胞的分化、增殖以及白细胞介素-17信使核糖核酸的表达。推测的机制是他克莫司抑制钙调神经磷酸酶以及T细胞受体刺激诱导的细胞分裂。由于Th17细胞参与同种异体移植排斥反应，本研究结果提示了他克莫司免疫抑制作用的新模型。此外，这些结果为他克莫司对同种异体移植排斥反应的治疗性免疫抑制作用提供了进一步的启示。
